Allogene Therapeutics, Inc.

As of May 4, 2022, Allogene Therapeutics, Inc. is considered overvalued due to significant financial losses, reflected in metrics like a price-to-book value of 0.81, a negative P/E ratio of -1.2018, and a year-to-date return of -42.72%, indicating a deterioration in its financial standing compared to peers and the S&P 500.

As of June 3, 2025, the market trend is mildly bearish, with mixed indicators showing some positive momentum from the MACD but overall bearish signals from Bollinger Bands, moving averages, and KST.

As of March 2022, the management team of Allogene Therapeutics, Inc. includes Dr. Arie Belldegrun (Executive Chairman), Dr. David Chang (President and CEO), and Mr. Joshua Kazam (Co-Founder). The Board of Directors also features independent members such as Mr. David Bonderman and Dr. Franz Humer.

Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company developing allogeneic T cell therapies for cancer treatment. It has a market cap of $284.35 million and reported a net profit loss of $60 million as of March 2025.

As of Jun 18, Allogene Therapeutics, Inc. has a market capitalization of 284.35 million, with net sales of 0.00 million and a net profit of -252.32 million over the latest four quarters. The company reported shareholder's funds of 422.18 million and total assets of 548.71 million as of Dec'24.